Changing the endocrine dependence of breast cancer: Data and hypotheses

Current Medicinal Chemistry

Volumn 21, Issue 9, 2014, Pages 1093-1106

  Nicolini, A ^a   Ferrari, P ^a   Biava, P M ^b   Carpi, A ^a  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Breast cancer; Cross talk; Hormone resistance; Hormone responsive; Oestrogen receptor; Oestrogen receptor phosphorylation; Progesterone receptor

Indexed keywords

ANASTROZOLE; BRCA1 PROTEIN; CASEIN KINASE II; CHEMOKINE RECEPTOR CXCR4; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; GEFITINIB; HEAT SHOCK PROTEIN; HISTONE ACETYLTRANSFERASE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IXABEPILONE; LETROZOLE; P21 ACTIVATED KINASE 1; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; TAMOXIFEN; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; UO 126; VASCULOTROPIN;

ACETYLATION; ARTICLE; AUTOPHAGY; BREAST CANCER; CELL CYCLE REGULATION; HORMONE RESISTANCE; HUMAN; HYPOXIA; LIGAND BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUMOYLATION; UBIQUITINATION; UPREGULATION;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENDOCRINE SYSTEM; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84896327395     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131201141741     Document Type: Article

References (187)

1. Lange, C. A.; Yee, D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr. Relat. Cancer, 2011, 18, C19-24.
2. Osborne, C. K. Steroid hormone receptors in breast cancer management. Breast. Cancer Res. Treat., 1998, 51, 227-238. (Pubitemid 29054556)
3. Clarke, R.; Liu, M. C.; Bouker, K. B.; Gu, Z.; Lee, R. Y.; Zhu, Y.; Skaar, T. C.; Gomez, B.; O'Brien, K.; Wang, Y.; Hilakivi-Clarke, L. A. Antioestrogen resistance in breast cancer and the role of oestrogen receptor signalling. Oncogene, 2003, 22, 7316-7339. (Pubitemid 37492898)
4. Bardou, V. J.; Arpino, G.; Elledge, R. M.; Osborne, C. K.; Clark, G. M. Progesterone receptor status significantly improves outcome prediction over oestrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol., 2003, 21, 1973-1979. (Pubitemid 46606386)
5. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31, 000 recurrences and 24, 000 deaths among 75, 000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet, 1992, 339, 71-85.
6. Robertson J. F. Ooestrogen receptor: a stable phenotype in breast cancer. Br. J. Cancer, 1996, 73, 5-12. (Pubitemid 26026252)
7. Hall, J. M.; Couse, J. F.; Korach, K. S. The multifaceted mechanisms of estradiol and oestrogen receptor signalling. J. Biol. Chem., 2001, 276, 36869-36872.
8. Nawaz, Z.; O'Malley, B. W. Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? Mol. Endocrinol., 2004, 18, 493-499. (Pubitemid 38328197)
9. Couse, J. F.; Korach, K. S. Oestrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev., 1999, 20, 358-417. (Pubitemid 30654784)
10. Russo, J.; Ao, X.; Grill, C.; Russo, I. H. Pattern of distribution of cells positive for oestrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat., 1999, 53, 217-227. (Pubitemid 29209891)
11. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schütz, G.; Umesono, K.; Blumberg, B.; Kastner, P. Mark, M.; Chambon, P.; Evans, R. M. The nuclear receptor superfamily: the second decade. Cell, 1995, 83, 835-839.
12. Tsai, M. J.; O'Malley, B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem., 1994, 63, 451-486. (Pubitemid 24218640)
13. Gronemeyer, H. Transcription activation by oestrogen and progesterone receptors. Annu. Rev. Genet., 1991, 25, 89-123. (Pubitemid 21903716)
14. Osborne, C. K.; Schiff, R; Fuqua, SA; Shou, J. Oestrogen receptor: current understanding of its activation and modulation. Clin. Cancer Res., 2001, 7, 4338s-4342s (Pubitemid 34031577)
15. Tora, L.; White, J.; Brou, C.; Tasset, D.; Webster, N.; Scheer, E.; Chambon P. The human oestrogen receptor has two independent nonacidic transcriptional activation functions. Cell, 1989, 59, 477-487. (Pubitemid 19284461)
16. Kuiper, G. G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U S A, 1996, 93, 5925-5930. (Pubitemid 26190778)
17. Mosselman, S.; Polman, J.; Dijkema, R. ER beta: identification and characterization of a novel human oestrogen receptor. FEBS Lett., 1996, 392, 49-53. (Pubitemid 26268330)
18. Zwart, W.; de Leeuw, R.; Rondaij, M.; Neefjes, J.; Mancini, M. A.; Michalides, R. The hinge region of the human oestrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. J. Cell. Sci., 2010, 123, 1253-1261.
19. Nilsson, S.; Mäkelä, S.; Treuter, E.; Tujague, M.; Thomsen, J.; Andersson, G.; Enmark, E.; Pettersson, K.; Warner, M.; Gustafsson, J. A. Mechanisms of oestrogen action. Physiol. Rev., 2001, 81, 1535-1565.
20. Le Romancer, M.; Poulard, C.; Cohen, P.; Sentis, S.; Renoir, J. M.; Corbo., L. Cracking the oestrogen receptor's posttranslational code in breast tumors. Endocr. Rev., 2011, 32, 597-622.
21. Auricchio, F.; Migliaccio, A. In vitro inactivation of ooestrogen receptor by nuclei: prevention by phosphatase inhibitors. FEBS Lett., 1980, 117, 224-226. (Pubitemid 11246507)
22. Auricchio, F.; Migliaccio, A.; Castoria, G; Rotondi, A.; Lastoria, S. Direct evidence of in vitro phosphorylation-dephosphorylation of the estradiol-17 beta receptor. Role of Ca2+-calmodulin in the activation of hormone binding sites. J. Steroid. Biochem., 1984, 20, 31-35. (Pubitemid 14127400)
23. Lannigan, D. A. Oestrogen receptor phosphorylation. Steroids, 2003, 68, 1-9.
24. Murphy, L. C.; Seekallu, S. V.; Watson, P. H. Clinical significance of oestrogen receptor phosphorylation. Endocr. Relat. Cancer, 2011, 18, R1-14.
25. Le Goff, P.; Montano, M. M.; Schodin, D. J.; Katzenellenbogen, B. S. Phosphorylation of the human oestrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J. Biol. Chem., 1994, 269, 4458-4466.
26. Valley, C. C.; Métivier, R.; Solodin, N. M.; Fowler, A. M.; Mashek, M. T.; Hill, L.; Alarid, E. T. Differential regulation of oestrogeninducible proteolysis and transcription by the oestrogen receptor alpha N terminus. Mol. Cell. Biol., 2005, 25, 5417-5428. (Pubitemid 40861697)
27. Grisouard, J.; Medunjanin, S.; Hermani, A.; Shukla, A.; Mayer, D. Glycogen synthase kinase-3 protects oestrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol. Endocrinol., 2007, 21, 2427-2439. (Pubitemid 47529356)
28. Arnold, S. F.; Obourn, J. D.; Jaffe, H.; Notides, A. C. Serine 167 is the major estradiol-induced phosphorylation site on the human oestrogen receptor. Mol. Endocrinol., 1994, 8, 1208-1214. (Pubitemid 24292597)
29. Joel, P. B.; Smith, J.; Sturgill, T. W.; Fisher, T. L.; Blenis, J.; Lannigan, D. A. pp90rsk1 regulates oestrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell. Biol., 1998, 18, 1978-1984. (Pubitemid 28152646)
30. Yamnik, R. L.; Holz, M. K. mTOR/S6K1 and MAPK/RSK signalling pathways coordinately regulate oestrogen receptor alpha serine 167 phosphorylation. FEBS Lett., 2010, 584, 124-128.
31. Colditz, G. A. Relationship between oestrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl. Cancer. Inst., 1998, 90, 814-823. (Pubitemid 28280547)
32. Crandall, D. L.; Busler, D. E.; Novak, T. J.; Weber, R. V.; Kral, J. G. Identification of oestrogen receptor beta RNA in human breast and abdominal subcutaneous adipose tissue. Biochem. Biophys. Res. Commun., 1998, 248, 523-526. (Pubitemid 28404453)
33. Michalides, R.; Griekspoor, A.; Balkenende, A.; Verwoerd, D.; Janssen, L.; Jalink, K.; Floore, A. K.; Velds, A.; Van't Veer, L.; Neefjes, J. Tamoxifen resistance by a conformational arrest of the oestrogen receptor alpha after PKA activation in breast cancer. Cancer. Cell, 2004, 5, 597-605. (Pubitemid 38748921)
34. Balasenthil, S.; Barnes, C. J.; Rayala, S. K.; Kumar, R. Oestrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett., 2004, 567, 243-247. (Pubitemid 38748399)
35. Cui, Y.; Zhang, M.; Pestell, R.; Curran, E. M.; Welshons, W. V.; Fuqua, S. A. Phosphorylation of oestrogen receptor alpha blocks its acetylation and regulates oestrogen sensitivity. Cancer Res., 2004, 64, 9199-9208. (Pubitemid 39665536)
36. Yang, C. S.; Xin, H. W.; Kelley, J. B.; Spencer, A.; Brautigan, D. L.; Paschal, B. M. Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions. Mol. Cell. Biol, 2007, 27, 3390-3404. (Pubitemid 46685215)
37. Murphy L. C.; Skliris G. P.; Rowan B. G.; Al-Dhaheri M.; Williams C; Penner C; Troup S.; Begic S.; Parisien M.; Watson, P. H. The relevance of phosphorylated forms of oestrogen receptor in human breast cancer in vivo. J. Steroid. Biochem. Mol. Biol, 2009, 114, 90-95.
38. Skliris, G. P.; Nugent, Z. J.; Rowan, B. G., Penner, C. R.; Watson, P. H.; Murphy, L. C. A phosphorylation code for ooestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer. Endocr. Relat. Cancer, 2010, 17, 589-597.
39. Popov V. M.; Wang C; Shirley L. A.; Rosenberg A.; Li, S.; Nevalainen, M.; Fu, M.; Pestell, R. G. The functional significance of nuclear receptor acetylation. Steroids, 2007, 72, 221-230. (Pubitemid 46273505)
40. Singh, BN; Zhang, G; Hwa, YL; Li, J; Dowdy, SC; Jiang, SW. Nonhistone protein acetylation as cancer therapy targets. Exp. Rev. Anticancer Ther., 2010, 10, 935-954.
41. Chen, H.; Lin, R. J.; Xie, W.; Wilpitz, D.; Evans, R. M. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell, 1999, 98, 675-686. (Pubitemid 29418958)
42. Kim, M. Y.; Hsiao, S. J; Kraus, W. L. A role for coactivators and histone acetylation in oestrogen receptor a-mediated transcription initiation. EMBO J., 2001, 20, 6084-6094 (Pubitemid 33049283)
43. Kim M. Y.; Woo E. M.; Chong, Y. T.; Homenko, D. R.; Kraus, W. L. Acetylation of oestrogen receptor a by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol. Endocrinol, 2006, 20, 1479-1493. (Pubitemid 43967558)
44. Wang, C; Fu, M.; Angeletti, R. H.; Siconolfi-Baez; L., Reutens, A. T.; Albanese, C; Lisanti, M. P.; Katzenellenbogen, B. S.; Kato, S.; Hopp, T.; Fuqua, S. A.; Lopez, G. N.; Kushner, P. J.; Pestell, R. G. Direct acetylation of the oestrogen receptor a hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem., 2001, 276, 18375-18383.
45. Ma, Y.; Fan, S.; Hu, C; Meng, Q.; Fuqua, S. A.; Pestell, R. G.; Tomita, Y. A.; Rosen, E. M. BRCA1 regulates acetylation and ubiquitination of oestrogen receptor-a. Mol. Endocrinol, 2010, 24, 76-90.
46. Nawaz, Z.; Lonard, D. M.; Dennis, A. P.; Smith, C. L.; O'Malley, B. W. Proteasome-dependent degradation of the human oestrogen receptor. Proc. Natl. Acad. Sci. USA, 1999, 96, 1858-1862. (Pubitemid 29117832)
47. Lonard, D. M.; Nawaz, Z.; Smith, C. L.; O'Malley, B. W. The 26S proteasome is required for oestrogen receptor-A and coactivator turnover and for efficient oestrogen receptor-A transactivation. Mol. Cell, 2000, 5, 939-948.
48. Wijayaratne, A. L.; McDonnell, D. P. The human oestrogen receptor-a is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective oestrogen receptor modulators. J. Biol. Chem., 2001, 276, 35684-35692.
49. Marsaud, V.; Gougelet, A.; Maillard, S; Renoir, JM. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous oestrogen receptor a (ERa), differentially affect ERa extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol. Endocrinol, 2003, 17, 2013-2027. (Pubitemid 37281794)
50. Stenoien, D. L.; Patel, K.; Mancini, M. G.; Dutertre, M., Smith, C. L.; O'Malley, B. W.; Mancini, M. A. FRAP reveals that mobility of ooestrogen receptor-a is ligand- and proteasome-dependent. Nat. Cell Biol., 2001, 3, 15-23. (Pubitemid 32114827)
51. Reid, G; Hübner, M. R.; Métivier, R.; Brand, H.; Denger, S.; Manu, D.; Beaudouin, J.; Ellenberg, J.; Gannon, F. Cyclic, proteasomem.ediated turnover of unliganded and liganded ERa on responsive promoters is an integral feature of oestrogen signalling. Mol. Cell, 2003, 11, 695-707. (Pubitemid 36385123)
52. Faus, H.; Haendler, B. Post-translational modifications of steroid receptors. Biomed. Pharmacother., 2006, 60, 520-528.
53. Sentis, S.; Le Romancer, M.; Bianchin, C; Rostan, M. C.; Corbo, L. Sumoylation of the oestrogen receptor a hinge region regulates its transcriptional activity. Mol. Endocrinol, 2005, 19, 2671-2684. (Pubitemid 41577242)
54. Gougelet, A.; Bouclier, C; Marsaud, V.; Maillard, S.; Mueller, S. O.; Korach, K. S.; Renoir, J. M. Oestrogen receptor a and p subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. J. Steroid. Biochem. Mol. Biol, 2005, 94, 71-81. (Pubitemid 40614520)
55. Sabbah, M.; Redeuilh, G.; Secco, C; Baulieu, E. E. The binding activity of oestrogen receptor to DNA and heat shock protein (Mr 90, 000) is dependent on receptor-bound metal. J. Biol. Chem., 1987, 262, 8631-8635.
56. Perissi, V.; Jepsen, K.; Glass, C. K.; Rosenfeld, M. G. Deconstructing repression: evolving models of co-repressor action. Nat. Rev. Genet., 2010, 11, 109-123.
57. Lonard, D. M.; O'Malley, B. W. The expanding cosmos of nuclear receptor coactivators. Cell, 2006, 125, 411-414.
58. Robyr, D.; Wolffe, A. P.; Wahli, W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol. Endocrinol, 2000, 14, 329-347. (Pubitemid 32266074)
59. Kushner, P. J.; Agard, D. A.; Greene, G. L.; Scanlan, T. S.; Shiau, A. K.; Uht, R. M.; Webb, P. Oestrogen receptor pathways to AP-1. J. Steroid. Biochem. Mol. Biol, 2000, 74, 311-317.
60. O'Lone, R.; Frith, M. C.; Karlsson, E. K.; Hansen, U. Genomic targets of nuclear oestrogen receptors. Mol. Endocrinol, 2004, 18, 1859-1875. (Pubitemid 39022608)
61. Saville, B.; Wormke, M.; Wang, F.; Nguyen, T.; Enmark, E., Kuiper, G.; Gustafsson, J. A.; Safe, S. Ligand-, cell-, and oestrogen receptor subtype (a/p)-dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem., 2000, 275, 5379-5387. (Pubitemid 30115168)
62. Björnström, L.; Sjöberg, M. 2004 Oestrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl. Recept., 2004, 2:3.
63. Quaedackers, M. E.; van den Brink, C. E.; van der Saag, P. T.; Tertoolen, L. G. Direct interaction between oestrogen receptor a and NF-kB in the nucleus of living cells. Mol. Cell. Endocrinol, 2007, 273, 42-50. (Pubitemid 47016743)
64. Kato, S.; Endoh, H.; Masuhiro, Y.; Kitamoto, T.; Uchiyama, S.; Sasaki, H.; Masushige, S.; Gotoh, Y.; Nishida, E.; Kawashima, H.; Metzger, D.; Chambon, P. Activation of the oestrogen receptor through phosphorylation by mitogen-activated protein kinase. Science, 1995, 270, 1491-1494.
65. Tremblay, A.; Tremblay, G. B.; Labrie, F.; Giguère, V. Ligandindependent recruitment of SRC-1 to oestrogen receptor p through phosphorylation of activation function AF-1. Mol. Cell, 1999, 3, 513-519. (Pubitemid 29292608)
66. Sauvé, K.; Lepage, J.; Sanchez, M.; Heveker, N.; Tremblay, A. Positive feedback activation of oestrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res., 2009, 69, 5793-5800.
67. Hammes, S. R.; Levin, E. R. Extranuclear steroid receptors: nature and actions. Endocr. Rev., 2007, 28, 726-741. (Pubitemid 350294293)
68. Olde, B.; Leeb-Lundberg, L. M. GPR30/GPER1: searching for a role in oestrogen physiology. Trends Endocrinol. Metab., 2009, 20, 409-416.
69. Pappas, T. C.; Gametchu, B.; Watson, C. S. Membrane oestrogen receptors identified by multiple antibody labeling and impededligand binding. FASEB J., 1995, 9, 404-410.
70. Levin, E. R. Plasma membrane oestrogen receptors. Trends Endocrinol. Metab., 2009, 20, 477-482.
71. Acconcia, F.; Manavathi, B.; Mascarenhas, J.; Talukder, A. H.; Mills, G.; Kumar, R. An inherent role of integrin-linked kinaseoestrogen receptor a interaction in cell migration. Cancer Res., 2006, 66, 11030-11038. (Pubitemid 44877003)
72. Björnström, L.; Sjöberg, M. Mechanisms of oestrogen receptor signalling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol, 2005, 19, 833-842. (Pubitemid 40397050)
73. Castoria, G.; Migliaccio, A.; Bilancio, A.; Di Domenico, M.; de Falco, A.; Lombardi, M.; Fiorentino, R.; Varricchio, L.; Barone, M. V.; Auricchio, F.. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J., 2001, 20, 6050-6059. (Pubitemid 33049280)
74. Simoncini, T.; Hafezi-Moghadam, A.; Brazil, D. P.; Ley, K.; Chin, W. W.; Liao, J. K. Interaction of ooestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature, 2000, 407, 538-541.
75. Song, R. X.; Zhang, Z.; Santen, R. J. Oestrogen rapid action via protein complex formation involving ERa and Src. Trends Endocrinol. Metab., 2005, 16, 347-353. (Pubitemid 41338739)
76. Pedram, A.; Razandi, M.; Evinger, A. J.; Lee, E.; Levin, E. R. Oestrogen inhibits ATR signalling to cell cycle checkpoints and DNA repair. Mol. Biol. Cell., 2009, 20, 3374-3389.
77. Azuma, K.; Urano, T.; Horie-Inoue, K.; Hayashi, S.; Sakai, R.; Ouchi, Y.; Inoue, S. Association of oestrogen receptor a and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Res., 2009, 69, 2935-2940.
78. Catalano, S.; Barone, I.; Giordano, C; Rizza, P.; Qi, H.; Gu, G.; Malivindi, R.; Bonofiglio, D.; Andò, S. Rapid estradiol/ERa signalling enhances aromatase enzymatic activity in breast cancer cells. Mol. Endocrinol, 2009, 23, 1634-1645.
79. Thomas, R. S.; Sarwar, N.; Phoenix, F.; Coombes, R. C.; Ali, S. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for oestrogen receptor-a activity. J. Mol. Endocrinol, 2008, 40, 173-184. (Pubitemid 351586826)
80. Chen, D.; Washbrook, E.; Sarwar, N.; Bates, G.; Pace, P.; Thirunuvakkarasu, V.; Taylor, J.; Epstein, R.; Fuller-Pace, F.; Egly, J. Phosphorylation of human oestrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene, 2002, 21, 4921-4931.
81. Medunjanin, S.; Hermani, A.; Servi, B. D.; Grisouard, J.; Rincke, G.; Mayer, D. Glycogen synthase kinase-3 interacts with and phosphorylates oestrogen receptor a and is involved in the regulation of receptor activity. J. Biol. Chem., 2005, 280, 33006-33014. (Pubitemid 41368350)
82. Park, K.; Krishnan, V.; O'Malley, B.; Yamamoto, Y.; Gaynor, R. Formation of an IKKalpha-dependent transcription complex is required for oestrogen receptor-mediated gene activation. Mol. Cell., 2005, 18, 71-82. (Pubitemid 40444649)
83. Pietras, R.; Arboleda, J.; Reese, D.; Wongvipat, N.; Pegram, M.; Ramos, L.; Gorman, C; Parker, M.; Sliwkowski, M.; Slamon, D. HER-2 tyrosine kinase pathway targets oestrogen receptor and promotes hormone independent growth in human breast cancer cells. Oncogene, 1995, 10, 2435-2446.
84. Dowsett, M.; Harper-Wynne, C; Boeddinghaus, I.; Salter, J.; Hills, M.; Dixon, M.; Ebbs, S.; Gui, G.; Sacks, N.; Smith, I.. HER-2 amplification impedes the antiproliferative effects of hormone therapy in oestrogen receptor-positive primary breast cancer. Cancer Res., 2001, 61, 8452-8458. (Pubitemid 33131124)
85. Knowlden, J.; Hutcheson, I.; Jones, H.; Madden, T.; Gee, J.; Harper, M.; Barrow, D.; Wakeling, A.; Nicholson, R. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifenresistant MCF-7 cells. Endocrinology, 2003, 144, 1032-1044. (Pubitemid 36262870)
86. Schiff, R.; Massarweh, S.; Shou, J.; Bharwani, L.; Mohsin, S.; Osborne, C. Cross-talk between oestrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res., 2004, 10, 331S-336S. (Pubitemid 38116639)
87. Shah, Y. M.; Rowan, B. G. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of oestrogen receptor (a) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol. Endocrinol, 2005, 9, 732-748. (Pubitemid 40349444)
88. Barone, I.; Iacopetta, D.; Covington, K. R.; Cui, Y.; Tsimelzon, A.; Beyer, A; Andò, S.; Fuqua, S. A. Phosphorylation of the mutant K303R oestrogen receptor a at serine 305 affects aromatase inhibitor sensitivity. Oncogene, 2010, 29, 2404-2414.
89. Giordano, C; Cui, Y.; Barone, I.; Ando, S.; Mancini, M. A.; Berno, V.; Fuqua, S. A. Growth factor-induced resistance to tamoxifen is associated with a mutation of oestrogen receptor a and its phosphorylation at serine 305. Breast Cancer Res., 2010, 119, 71-85.
90. Barone, I.; Cui, Y.; Herynk, M. H.; Corona-Rodriguez, A.; Giordano, C; Selever, J.; Beyer, A.; Andò, S.; Fuqua, SA. Expression of the K303R oestrogen receptor-a breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res., 2009, 69, 4724-4732.
91. Murphy, L.; Cherlet, T.; Lewis, A.; Banu, Y.; Watson, P. New insights into oestrogen receptor function in human breast cancer. Ann. Med., 2003, 35, 614-31. (Pubitemid 38005317)
92. Zhang, X. T.; Kang, L. G.; Ding, L., Vranic, S.; Gatalica, Z.; Wang, Z. Y. A positive feedback loop of ER-a36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene, 2011, 30, 770-780.
93. Shi, L.; Dong, B.; Li, Z.; Lu, Y.; Ouyang, T.; Li, J.; Wang, T.; Fan, Z.; Fan, T.; Lin, B.; Wang, Z.; Xie, Y. Expression of ER-a36, a novel variant of oestrogen receptor a, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol, 2009, 27, 3423-3429.
94. Skliris, G. P.; Leygue, E.; Curtis-Snell, L.; Watson, P. H.; Murphy, L. C. Expression of ooestrogen receptor-P in ooestrogen receptor-a negative human breast tumours. Br. J. Cancer, 2006, 95, 616-626. (Pubitemid 44325902)
95. Levin, E. R. Cellular Functions of the Plasma Membrane Oestrogen Receptor. Trends Endocrinol. Metab., 1999, 10, 374-377.
96. Fischle, W.; Wang, Y.; Allis, C. D. Binary switches and modification cassettes in histone biology and beyond. Nature, 2003, 425, 475-479. (Pubitemid 37237036)
97. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications. Nature, 2000, 403, 414-415.
98. Airaksinen, M. S; Saarma, M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci., 2002, 3, 383-394. (Pubitemid 135706635)
99. Ichihara, M.; Murakumo, Y.; Takahashi, M. RET and neuroendocrine tumors. Cancer Lett., 2004, 204, 197-211. (Pubitemid 38167723)
100. Tozlu, S. Identification of novel genes that co-cluster with oestrogen receptor alpha in breast tumor biopsy specimens, using a largescale real-time reverse transcription-PCR approach. Endocr. Relat. Cancer, 2006, 13, 1109-1120. (Pubitemid 46212566)
101. Plaza-Menacho, I.; Morandi, A.; Robertson, D.; Pancholi, S.; Drury, S.; Dowsett, M.; Martin, L. A.; Isacke, C. M. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene, 2010, 29, 4648-4657.
102. Boulay, A.; Breuleux, M.; Stephan, C.; Fux, C.; Brisken, C.; Fiche, M.; Wartmann, M.; Stumm, M.; Lane, H. A.; Hynes, N. E. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res., 2008, 68, 3743-3751.
103. Kang, J.; Qian, P. X.; Pandey, V.; Perry,. JK.; Miller, L. D.; Liu, E. T.; Zhu, T.; Liu, D. X.; Lobie, P. E. Artemin is oestrogen regulated and mediates antioestrogen resistance in mammary carcinoma. Oncogene, 2010, 29, 3228-3240
104. Esseghir, S.; Todd, S. K.; Hunt, T.; Poulsom, R.; Plaza-Menacho, I.; Reis-Filho,. JS.; Isacke, C. M. A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. Cancer Res., 2007, 67, 11732-11741.
105. Kuno, R.; Yoshida, Y.; Nitta, A.; Nabeshima, T.; Wang, J.; Sonobe, Y.; Kawanokuchi, J.; Takeuchi, H.; Mizuno, T.; Suzumura, A. The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes. Brain Res., 2006, 116, 12-18. (Pubitemid 44485022)
106. Appel, E.; Kolman, O.; Kazimirsky, G.; Blumberg P. M.; Brodie, C. Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli. Neuroreport., 1997, 8, 3309-3312. (Pubitemid 27461386)
107. de Visser, K. E.; Eichten, A.; Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer, 2006, 6, 24-37. (Pubitemid 43053650)
108. Ben-Baruch, A. The multifaceted roles of chemokines in malignancy. Cancer Met. Rev., 2006, 25, 357-371. (Pubitemid 44922355)
109. Thangavel, C.; Dean, J. L.; Ertel, A.; Knudsen, K. E.; Aldaz, C. M.; Witkiewicz, A. K.; Clarke, R.; Knudsen, E. S. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapyresistant breast cancer. Endocr. Rel. Cancer, 2011, 18, 333-345.
110. Lukas, J.; Bartkova, J.; Bartek, J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol. Cell. Biol., 1996, 16, 6917-6925. (Pubitemid 26389751)
111. Witzel, I. I.; Koh, L. F.; Perkins, N. D. Regulation of cyclin D1 gene expression. Biochem. Soc. Trans., 2010, 38, 217-222.
112. Samaddar, J. S.; Gaddy, V. T.; Duplantier, J.; Thandavan, S. P.; Shah, M.; Smith, M. J.; Browning, D.; Rawson, J.; Smith, S. B.; Barrett, J. T.; Schoenlein, P. V. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antioestrogen resistance. Mol. Cancer Ther., 2008, 7, 2977-87.
113. Crawford, A. C.; Riggins, R. B.; Shajahan, A. N.; Zwart, A.; Clarke, R. Co-inhibition of BCL-W and BCL2 restores antioestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. PLoS One, 2010, 5, e8604.
114. Dhasarathy, A.; Kajita, M.; Wade, P. A. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of oestrogen receptor-alpha. Mol. Endocrinol., 2007, 21, 2907-2918. (Pubitemid 350223504)
115. Ye, Y.; Xiao, Y.; Wang, W.; Yearsley, K.; Gao, J. X.; Barsky, S. H. ERalpha suppresses slug expression directly by transcriptional repression. Biochem. J., 2008, 416, 179-187.
116. Luqmani, Y. A.; Al Azmi, A.; Al Bader, M.; Abraham, G.; El Zawahri, M. Modification of gene expression induced by siRNA targeting of oestrogen receptor alpha in MCF7 human breast cancer cells. Int. J. Oncol., 2009, 34, 231-242.
117. Luqmani, Y. A.; Al Mulla, F.; Al Saleh, S. siRNA indiced loss of oestrogen receptor in human breast cancer cells is associated with an epithelial to mesenchymal transition. Int. J. Mol. Med., 2010, 26, A 140.
118. Al Saleh, S.; Luqmani, Y. A. Effect of tyrosine kinase inhibitors is enhanced in endocrine-resistant breast cancer cells displaying increased metastatic potential. Int. J. Mol. Med., 2010, 26, A 141.
119. Parker, K. K.; Brock, A. L.; Brangwynne, C.; Mannix, R. J.; Wang, N.; Ostuni, E.; Geisse, N. A.; Adams, J. C.; Whitesides, G. M.; Ingber, D. E. Directional control of lamellipodia extension by constraining cell shape and orienting cell tractional forces. FASEB J., 2002, 16, 1195-1204. (Pubitemid 34815407)
120. Sphyris, N.; Mani, S. A. The importance of epithelial mesenchymal transition in breast cancer. Curr Breast Cancer Rep., 2009, 1, 229-237.
121. De Cremoux, P.; Grandin, L.; Diéras, V.; Savignoni, A.; Degeorges, A.; Salmon, R.; Bollet, M. A.; Reyal, F.; Sigal-Zafrani, B.; Vincent-Salomon, A.; Sastre-Garau, X.; Magdelénat, H.; Mignot, L.; Fourquet, A.; Breast Cancer Study Group of the Institut Curie. Urokinase-type plasminogen activator and plasminogen-activatorinhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res., 2009, 29, 1475-1482.
122. Coradini, D. Hypoxia and oestrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antioestrogens. Cell. Mol. Life. Sci., 2004, 61, 76-82. (Pubitemid 38121901)
123. Kurebayashi, J.; Otsuki, T.; Moriya, T.; Sonoo, H. Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn. J. Cancer. Res., 2001, 92, 1093-1101. (Pubitemid 33041178)
124. Conley, S. J. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U S A, 2012, 109, 2784-2789.
125. Yi, J. M.; Kwon, H. Y.; Cho, J. Y.; Lee, Y. J. Oestrogen and hypoxia regulate oestrogen receptor alpha in a synergistic manner. Biochem. Biophys. Res. Commun., 2009, 378, 842-846.
126. Seifeddine, R.; Dreiem, A.; Tomkiewicz, C.; Fulchignoni-Lataud, M. C.; Brito, I.; Danan, J. L.; Favaudon, V.; Barouki, R.; Massaad-Massade, L. Hypoxia and oestrogen co-operate to regulate gene expression in T-47D human breast cancer cells. J. Steroid. Biochem. Mol. Biol., 2007, 104, 169-179. (Pubitemid 46901032)
127. Scherbakov, A. M.; Lobanova, Y. S.; Shatskaya, V. A.; Krasil'nikov, M. A. The breast cancer cells response to chronic hypoxia involves the opposite regulation of NF-kB and oestrogen receptor signalling. Steroids, 2009, 74, 535-542.
128. Johnston, S. R. New strategies in oestrogen receptor-positive breast cancer. Clin. Cancer. Res., 2010, 16, 1979-1987.
129. Johnston, S.; Pippen, J. Jr.; Pivot, X.; Lichinitser, M.; Sadeghi, S.; Dieras, V.; Gomez, H. L.; Romieu, G.; Manikhas, A.; Kennedy, M. J. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptorpositive metastatic breast cancer. J. Clin. Oncol., 2009, 27, 5538-5546.
130. Smith, I. E.; Walsh, G.; Skene, A.; Llombart, A.; Mayordomo, J. I.; Detre, S.; Salter, J.; Clark, E.; Magill, P.; Dowsett, M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol., 2007, 25, 3816-3822. (Pubitemid 47477255)
131. Kaufman, P. A.; Ferrero, J. M.; Bourgeois, H.; Kennecke, H.; De Boer, R.; Jacot, W.; McGreivy, J.; Suzuki, S.; Loh, E.; Robertson, J. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res., 2010, 70, 76s.
132. Johnston, S. R.; Martin, L. A.; Leary, A.; Head, J.; Dowsett, M. Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J. Steroid. Biochem. Mol. Biol., 2007, 106, 180-186. (Pubitemid 47362648)
133. Baselga, J.; Campone, M.; Piccart, M.; Burris, H. A. 3rd; Rugo, H. S.; Sahmoud, T.; Noguchi, S.; Gnant M.; Pritchard, K. I.; Lebrun, F.; Beck, J. T.; Ito, Y.; Yardley, D.; Deleu, I.; Perez, A.; Bachelot, T.; Vittori, L.; Xu, Z.; Mukhopadhyay, P.; Lebwohl D.; Hortobagyi, G. N. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N. Engl. J. Med., 2012, 366, 520-529.
134. Boulay, A.; Breuleux, M.; Stephan, C.; Fux, C.; Brisken, C.; Fiche, M.; Wartmann, M.; Stumm, M.; Lane, H. A.; Hynes, N. E. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer Cancer Res., 2008, 68, 3743-3751.
135. Akeno-Stuart, N.; Croyle, M.; Knauf, J. A.; Malaguarnera, R.; Vitagliano, D.; Santoro, M.; Stephan, C; Grosios, K.; Wartmann, M.; Cozens, R.; Caravatti, G.; Fabbro, D.; Lane, H. A.; Fagin, J. A. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res., 2007, 67, 6956-6964. (Pubitemid 47105543)
136. Isaacs, C; Herbolsheimer, P.; Liu, M. C.; Wilkinson, M.; Ottaviano, Y.; Chung, G. G.; Warren, R.; Eng-Wong, J.; Cohen, P.; Smith, K. L.; Creswell, K.; Novielli, A.; Slack, R. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res. Treat., 2011, 125, 137-143.
137. Chow, L. W.; Yip, A. Y.; Loo, W. T.; Toi, M. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. Cancer Lett., 2008, 262, 232-238.
138. Kronblad, A.; Hedenfalk, I.; Nilsson, E.; Påhlman, S.; Landberg, G. ERK1/2 inhibition increases antioestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene, 2005, 24, 6835-6841. (Pubitemid 41487042)
139. Cooper, C; Liu, G.; Niu, Y.; Santos, S.; Murphy, L.; Watson, P. Intermittent hypoxia induces proteasome-dependent downregulation of oestrogen receptor a in human breast carcinoma. Clin. Cancer Res., 2004, 10, 8720-8727. (Pubitemid 40053441)
140. Creighton, C. J.; Hilger, A. M.; Murthy, S.; Rae, J. M.; Chinnaiyan, A. M.; El-Ashry, D. Activation of mitogen-activated protein kinase in oestrogen receptor a-positive breast cancer cells in vitro induces an in vivo molecular phenotype of oestrogen receptor a-negative human breast tumors. Cancer Res., 2006, 66, 3903-3911.
141. Lopez-Tarruella, S.; Schiff, R. The dynamics of oestrogen receptor status in breast cancer: re-shaping the paradigm. Clin. Cancer Res., 2007, 13, 6921-6925. (Pubitemid 350276870)
142. West, N. R.; Watson, P. H. S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene, 2010, 29, 2083-2092.
143. Cyrus, K.; Wehenkel, M.; Choi, E. Y.; Lee, H.; Swanson, H.; Kim, K. B. Jostling for position: optimizing linker location in the design of oestrogen receptor-targeting PROTACs. Chem. Med. Chem., 2010, 5, 979-985.
144. Periyasamy-Thandavan, S.; Jackson, W. H.; Samaddar, J. S.; Erickson, B.; Barrett, J. R.; Raney, L.; Gopal, E.; Ganapathy, V.; Hill, W. D.; Bhalla, K. N.; Schoenlein, P. V. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspasedependent cell death in antioestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy, 2010, 6, 19-35.
145. Thomas, S.; Thurn, K. T.; Biçaku, E.; Marchion, D. C.; Münster, P. N. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res. Treat., 2011, 130, 437-447.
146. Shu, C. W.; Madiraju, C; Zhai, D.; Welsh, K.; Diaz, P.; Sergienko, E.; Sano, R.; Reed, J. C. High-throughput fluorescence assay for small-molecule inhibitors of autophagins/Atg4. J. Biomol. Screen., 2011, 16, 174-182.
147. Zhang, L.; Yu, J.; Pan, H.; Hu, P.; Hao, Y.; Cai, W.; Zhu, H.; Yu, AD.; Xie, X.; Ma, D.; Yuan, J. Small molecule regulators of autophagy identified by an image-basedhigh-throughput screen. Proc. Natl. Acad. Sci. U S A, 2007, 104, 19023-19028.
148. Berx, G.; Raspé, E.; Christofori, G.; Thiery, J. P.; Sleeman, J. P. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin. Exp. Metastasis, 2007, 24, 587-597. (Pubitemid 50000849)
149. Santisteban, M.; Reiman, J. M.; Asiedu, M. K.; Behrens, M. D.; Nassar, A.; Kalli, K. R.; Haluska, P.; Ingle, J. N.; Hartmann, L. C.; Manjili, M. H.; Radisky, D. C.; Ferrone, S.; Knutson, K. L. Immuneinduced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res., 2009, 69, 2887-2895.
150. Willipinski-Stapelfeldt, B.; Riethdorf, S.; Assmann, V.; Woelfle, U.; Rau, T.; Sauter, G.; Heukeshoven, J.; Pantel, K. Changes in cytoskeletal protein composition indicative of an epithelialmesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin. Cancer Res., 2005, 11, 8006-8014. (Pubitemid 41698741)
151. Das, S.; Becker, B. N.; Hoffmann, F. M.; Mertz, J. E. Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. BMC Cell Biol., 2009, 10, 94.
152. Sarrió, D.; Rodriguez-Pinilla, S. M.; Hardisson, D.; Cano, A.; Moreno-Bueno, G.; Palacios, J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res., 2008, 68, 989-997. (Pubitemid 351272216)
153. Thompson, E. W.; Newgreen, D. F.; Tarin, D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res., 2005, 65, 5991-5595.
154. Yan, W.; Cao, Q. J.; Arenas, R. B.; Bentley, B.; Shao, R. GATA3 inhibits breast cancermetastasis through the reversal of epithelialmesenchymal transition. J. Biol. Chem., 2010, 285, 14042-14051.
155. Nicolini, A.; Carpi, A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomed. Pharmacother., 2005, 59, 253-263. (Pubitemid 40799180)
156. Nicolini, A.; Carpi, A.; Rossi, G. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters. J. Immunother., 2005, 28, 276-279. (Pubitemid 40593994)
157. Nicolini, A.; Carpi, A.; Rossi, G. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. Cancer Lett., 2007, 251, 330-338. (Pubitemid 46669804)
158. Nicolini, A.; Carpi, A.; Ferrari, P.; Rossi, G. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study. Cancer Lett., 2008, 263, 122-129.
159. Nicolini, A.; Carpi, A.; Rossi, G. Cytokines in breast cancer. Cytokine Growth Factor Rev., 2006, 17, 325-337. (Pubitemid 44572877)
160. Nicolini, A.; Carpi, A. Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med. Res. Rev., 2009, 29, 436-471.
161. Carpi, A.; Nicolini, A.; Antonelli, A.; Ferrari, P.; Rossi, G. Cytokines in the management of high risk or advanced breast cancer: an update and expectation. Curr. Cancer Drug Targets, 2009, 9, 888-903.
162. Nicolini, A.; Rossi, G.; Ferrari, P.; Carpi, A. Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer. Biomed. Pharmacother., 2013, in publication.
163. He, X.; Zheng, Z.; Song, T.; Wei, C.; Ma H., Ma, Q., Zhang, Y., Xu, Y., Shi, W., Ye, Q., Zhong, H. c-Abl regulates oestrogen receptor alpha transcription activity through its stabilization by phosphorylation. Oncogene, 2010, 29, 2238-2251.
164. Rogatsky, I.; Trowbridge, J. M.; Garabedian, M. J. Potentiation of human oestrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J. Biol. Chem., 1999, 274, 22296-22302.
165. Sheeler, C. Q.; Singleton, D. W.; Khan, S. A. Mutation of serines 104, 106, and 118 inhibits dimerization of the human oestrogen receptor in yeast. Endocr. Res., 2003, 29, 237-255. (Pubitemid 36828496)
166. Ali, S.; Metzger, D.; Bornert, J. M.; Chambon, P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human ooestrogen receptor A/B region. EMBO J., 1993, 12, 1153-1160. (Pubitemid 23095864)
167. Chen, D.; Riedl, T.; Washbrook, E.; Pace, P. E.; Coombes, R. C.; Egly, J. M.; Ali, S. Activation of oestrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol. Cell., 2000, 6, 127-137.
168. Masuhiro, Y.; Mezaki, Y.; Sakari, M.; Takeyama, K.; Yoshida, T.; Inoue, K.; Yanagisawa, J.; Hanazawa, S.; O'Malley, B. W.; Kato, S. Splicing potentiation by growth factor signalsvia oestrogen receptor phosphorylation. Proc. Natl. Acad. Sci. U S A, 2005, 102, 8126-8131. (Pubitemid 40800054)
169. Weitsman G. E.; Li, L.; Skliris, G. P.; Davie, J. R.; Ung, K.; Niu, Y.; Curtis-Snell, L.; Tomes, L.; Watson, P. H.; Murphy, L. C. Oestrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of oestrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res., 2006, 66, 10162-10170. (Pubitemid 44672071)
170. González, L.; Zambrano, A.; Lazaro-Trueba, I.; Lopéz, E.; González, J. J.; Martín-Pérez, J; Aranda, A. Activation of the unliganded oestrogen receptor by prolactin in breast cancer cells. Oncogene, 2009, 28, 1298-1308.
171. Weitsman G. E.; Weebadda, W.; Ung, K.; Murphy L. C. Reactive oxygen species induce phosphorylation of serine 118 and 167 on oestrogen receptor alpha. Breast Cancer Res. Treat., 2009, 118, 269-279.
172. Britton, D. J.; Scott, G. K.; Schilling, B.; Atsriku, C.; Held, J. M.; Gibson, B. W.; Benz, C. C.; Baldwin, M. A. A novel serine phosphorylation site detected in the N-terminal domain of oestrogen receptor isolated from human breast cancer cells. J. Am. Soc. Mass Spectrom., 2008, 19, 729-740.
173. Campbell, R. A.; Bhat-Nakshatri, P.; Patel, N. M.; Constantinidou, D.; Ali, S.; Nakshatri, H. Phosphatidylinositol 3-kinase/AKT-mediated activation of oestrogen receptor alpha: a new model for anti-oestrogen resistance. J. Biol. Chem., 2001, 276, 9817-9824.
174. Yamnik, R. L.; Digilova, A.; Davis, D. C.; Brodt, Z. N.; Murphy, C. J.; Holz, M. K.. S6 kinase 1 regulates oestrogen receptor alpha in control of breast cancer cell proliferation. J. Biol. Chem., 2009, 284, 6361-6369.
175. Park, S.; Song, J.; Joe, C. O.; Shin, I. Akt stabilizes oestrogen receptor alpha with the concomitant reduction in its transcriptional activity. Cell Signal., 2008, 20, 1368-1374.
176. Chen, D.; Pace, P. E.; Coombes, R. C.; Ali, S. Phosphorylation of human oestrogen receptor alpha by protein kinase A regulates dimerization. Mol. Cell. Biol., 1999, 19, 1002-1015. (Pubitemid 29046844)
177. Williams, C. C.; Basu, A.; El-Gharbawy, A.; Carrier, L. M.; Smith, C. L.; Rowan, B. G. Identification of four novel phosphorylation sites in oestrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC Biochem., 2009, 10, 36.
178. Tharakan, R.; Lepont, P.; Singleton, D.; Kumar, R.; Khan, S. Phosphorylation of oestrogen receptor alpha, serine residue 305 enhances activity. Mol. Cell. Endocrinol., 2008, 295, 70-78.
179. Wang, R. A.; Mazumdar, A.; Vadlamudi, R. K.; Kumar, R. P21-activated kinase-1 phosphorylates and transactivates oestrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J., 2002, 21, 5437-5447. (Pubitemid 35231023)
180. Lee, H.; Bai, W. Regulation of oestrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol. Cell. Biol., 2002, 22, 5835-5845. (Pubitemid 34815832)
181. Acconcia, F.; Ascenzi, P.; Bocedi, A.; Spisni, E.; Tomasi, V.; Trentalance, A.; Visca, P.; Marino, M. Palmitoylation-dependent oestrogen receptor alpha membrane localization: regulation by 17betaestradiol. Mol. Biol. Cell., 2005, 16, 231-237. (Pubitemid 40028339)
182. Castoria, G.; Migliaccio, A.; Green, S.; Di Domenico, M.; Chambon, P.; Auricchio, F. Properties of a purified estradiol-dependent calf uterus tyrosine kinase. Biochemistry, 1993, 32, 1740-1750. (Pubitemid 23066447)
183. Arnold, S. F.; Obourn, J. D.; Jaffe, H.; Notides, A. C. Phosphorylation of the human oestrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol. Endocrinol., 1995, 9, 24-33.
184. Arnold, S. F.; Vorojeikina, D. P.; Notides, A. C. Phosphorylation of tyrosine 537 on the human oestrogen receptor is required for binding to an oestrogen response element. J. Biol. Chem., 1995, 270, 30205-3012.
185. Arnold, S. F.; Melamed, M.; Vorojeikina, D. P.; Notides, A. C.; Sasson, S. Estradiol-binding mechanism and binding capacity of the human oestrogen receptor is regulated by tyrosine phosphorylation. Mol. Endocrinol., 1997, 11, 48-53. (Pubitemid 27021253)
186. Márquez, D. C.; Lee, J.; Lin, T.; Pietras, R. J. Epidermal growth factor receptor and tyrosine phosphorylation of oestrogen receptor. Endocrine, 2001, 16, 73-81. (Pubitemid 34169611)
187. Nicolini, A.; Carpi, A.; Ferrari, P.; Rossi, G. Hormoneimmunotherapy in metastatic breast cancer: a mini-review and an update. 2013, submitted.